Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CDK5 | Q00535 | 6/20 | 0.45 |
| ▸ | CDK5R1 | Q15078 | 6/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.36 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.35 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.35 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.35 |
| ▸ | JAK2 | O60674 | 2/20 | 0.35 |
| ▸ | JAK1 | P23458 | 2/20 | 0.35 |
| ▸ | TYK2 | P29597 | 2/20 | 0.35 |
| ▸ | JAK3 | P52333 | 2/20 | 0.35 |
| ▸ | CDK1 | P06493 | 2/20 | 0.34 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.33 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.33 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20208862 | 0.88 | CDK5 (0.44) | CDK5CDK5R1ADORA1ADORA2APRKD3 | |
| SCHEMBL25768308 | 0.88 | CDK5 (0.58) | CDK5CDK5R1CDK1CCNB2CCNB1 | |
| SCHEMBL20806161 | 0.87 | CDK5 (0.43) | CDK5CDK5R1ADORA1ADORA2APRKD3 | |
| SCHEMBL22020964 | 0.84 | CDK5 (0.41) | CDK5CDK5R1ADORA1ADORA2APRKD3 | |
| SCHEMBL19660229 | 0.81 | HTT (0.40) | CDK5CDK5R1ADORA1ADORA2AMAPK8 | |
| SCHEMBL21347453 | 0.80 | MAPK8 (0.40) | ADORA1ADORA2AMAPK8MAPK9 | |
| SCHEMBL20208722 | 0.78 | ADORA1 (0.37) | CDK5CDK5R1ADORA1ADORA2APRKD3 | |
| SCHEMBL19660601 | 0.78 | CDK5 (0.33) | CDK5CDK5R1CDK1 | |
| SCHEMBL26734570 | 0.75 | CDK5 (0.47) | CDK5CDK5R1ADORA1ADORA2APRKD3 | |
| SCHEMBL22399470 | 0.74 | CDK5 (0.47) | CDK5CDK5R1ADORA1CDK1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-02 | — | — | US | disclosed |
| WO-2023154528-A1 | STEREOSELECTIVE TECHNOLOGIES FOR CHIRAL COMPOUNDS | WAVE LIFE SCIENCES LTD. (SG) | 2023-08-17 | — | — | WO | disclosed |
| WO-2020191252-A1 | TECHNOLOGIES USEFUL FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2020-09-24 | — | — | WO | disclosed |
| WO-2019055951-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | WAVE LIFE SCIENCES LTD. (SG) | 2019-03-21 | — | — | WO | disclosed |
| WO-2019032607-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-02-14 | — | — | WO | disclosed |
| WO-2019032612-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2019-02-14 | — | — | WO | disclosed |
| WO-2018098264-A1 | COMPOSITIONS AND METHODS FOR PHOSPHORAMIDITE AND OLIGONUCLEOTIDE SYNTHESIS | WAVE LIFE SCIENCES LTD. (SG) | 2018-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230348524-A1 | TECHNOLOGIES FOR OLIGONUCLEOTIDE PREPARATION | POLRMT, DCLRE1B, RNGTT | CDK5 2352/4885CDK5R1 3009/4885ADORA1 410/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.